Compare SST & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SST | SER |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 29.3M |
| IPO Year | N/A | 2018 |
| Metric | SST | SER |
|---|---|---|
| Price | $4.40 | $2.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $13.00 |
| AVG Volume (30 Days) | 13.3K | ★ 66.7K |
| Earning Date | 03-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | $116,000.00 |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.90 | $1.71 |
| 52 Week High | $15.00 | $7.92 |
| Indicator | SST | SER |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 45.01 |
| Support Level | $4.09 | $2.76 |
| Resistance Level | $4.60 | $3.06 |
| Average True Range (ATR) | 0.25 | 0.30 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 15.27 | 43.52 |
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.